Wake-Promoting Drug Helps Early Morning Shift Workers Beat Biological Sleep Cycles
Clinical trial shows solriamfetol significantly improves alertness and performance in workers who start before sunrise.
Summary
A new clinical trial found that solriamfetol, a wake-promoting drug, significantly helps early morning shift workers stay alert and perform better despite working against their natural sleep cycles. The study included 78 workers with shift work disorder who start between 3-7 AM. Those taking solriamfetol showed improved alertness, productivity, and safety compared to placebo over four weeks. This addresses a major gap since no previous trials tested treatments specifically for early morning workers, despite this being the most common shift schedule affecting millions.
Detailed Summary
Millions of workers start their shifts between 3-7 AM, forcing them awake when their brains are biologically programmed to sleep. This creates shift work disorder, characterized by severe fatigue, reduced concentration, and increased safety risks. Until now, no clinical trials had specifically tested treatments for this most common type of shift work.
Researchers at Mass General Brigham conducted the first clinical trial targeting early morning shift workers with shift work disorder. The study included 78 participants randomly assigned to receive either solriamfetol (Sunosi) or placebo over four weeks. Solriamfetol is already FDA-approved for treating excessive sleepiness in sleep apnea and narcolepsy patients.
Participants taking solriamfetol showed significant improvements in alertness, productivity, and overall job performance compared to the placebo group. The drug helped workers stay awake and function better throughout their full shifts without significantly disrupting their ability to sleep later.
Shift work disorder affects roughly 25% of the workforce and is linked to serious health and safety concerns including reduced mental sharpness, increased workplace injuries, and higher car accident risk. Previous wake-promoting medications like modafinil were mainly studied in overnight workers and could interfere with daytime sleep.
This research offers hope for the millions struggling with early morning schedules, potentially reducing fatigue-related mistakes and improving workplace safety. However, the study was relatively small and short-term, requiring larger trials to confirm long-term safety and effectiveness.
Key Findings
- Solriamfetol significantly improved alertness in early morning shift workers with shift work disorder
- First clinical trial specifically targeting workers who start between 3-7 AM
- Drug enhanced productivity and safety without disrupting later sleep patterns
- 25% of workers operate outside standard schedules, many unaware they're shift workers
- Shift work disorder increases workplace injuries and car accident risk
Methodology
This is a news report from ScienceDaily covering a clinical trial published in NEJM Evidence. The research was conducted by credible investigators at Mass General Brigham, a reputable medical institution.
Study Limitations
The study included only 78 participants over four weeks, limiting conclusions about long-term safety and effectiveness. The article doesn't provide detailed side effect profiles or cost considerations for widespread implementation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.